Cancer is a growing concern for HIV-infected people, and screening plays a major role in alleviating the burden it causes. We sought to investigate the levels and determinants of breast cancer screening (BCS) and cervical cancer screening (CCS) in HIV-infected women as compared with the general population.
Introduction
In recent years, cancer has consistently been described as a growing burden among people living with HIV (PLWHIV) in Western countries [1] [2] [3] [4] [5] [6] . In 2010, it accounted for one-third of all deaths among HIV-infected people in France [7] . Cancer control strategies for limiting this burden in the future are based on prevention and especially on screening (secondary prevention) [8] . In particular, breast cancer screening (BCS) and cervical cancer screening (CCS) are widely used to alleviate the burden of two of the major gynaecological cancers.
Breast cancer is one of the most prevalent non-AIDSrelated malignancies [1, 4] . Although the change in its incidence over time among PLWHIV is unclear [2, 6, 9] , breast cancer is becoming a matter of concern in this population, which is now ageing and experiencing more and more age-related conditions, such as cancer [3] [4] [5] 9, 10] . Cervical cancer is one of the most common AIDS-defining cancers [4, 5] . It occurs more often among HIV-infected than HIV-uninfected women [2, 6, [11] [12] [13] [14] [15] [16] [17] [18] [19] and appears to be diagnosed at a later stage, more aggressive and less responsive to treatment [15, [17] [18] [19] [20] than in the general population.
Previous research showed high variability in BCS (24-67% [21] [22] [23] [24] [25] [26] ) and CCS (25-83% [20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ) rates among HIV-infected women, which could have been partly attributable to over/underestimations caused by differences in the study populations (urban [31] , low-income [33] , mostly African-Americans [27, 34] and smokers [35] ), in data collection (self-reported [20, 22, [27] [28] [29] [30] [31] [32] [33] , measured [23] [24] [25] [26] [34] [35] [36] [37] and repeated [34, 38] ) and in the definitions (screening during the study period [22, 23, 28] and being up to date for screening measured with different cut-offs [21, [23] [24] [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] 37] ). Studies generally report lower [21, 24, 36, 37] or similar [29, 30] levels of BCS and CCS in HIV-infected women compared with the general population. Nevertheless, although the marked differences in demographic characteristics between HIV-infected women and those in the general population are likely to influence the level of screening, these characteristics were not taken into account in most of those previous studies. The barriers to cancer screening uptake in HIV-infected women reported in previous studies [20] [21] [22] [23] [28] [29] [30] [31] [34] [35] [36] [37] [38] [39] were a younger or older age, unfavourable socioeconomic conditions, not having any health care coverage, an insufficient medical follow-up, negative health behaviours, a high viral load and a low CD4 count. As HIVinfected women live with a chronic disease and receive specific care, it can be assumed that the factors associated with cancer screening might differ from those observed in the general population. However, to our knowledge no study has formally compared the determinants of cancer screening uptake between PLWHIV and the general population.
We sought to evaluate the levels and determinants of BCS and CCS among HIV-infected women and to specifically compare them with those in the general population, using a large national representative survey among PLWHIV in France.
Methods

Sources of data
Data on HIV-infected individuals were obtained from the Agence Nationale de Recherche sur le Sida et les H epatites Virales (ANRS)-Vespa2 study, a national, representative, cross-sectional survey aimed primarily at assessing the various aspects of the socioeconomic conditions and health status of PLWHIV in France [40, 41] . The study was conducted between April 2011 and January 2012 in 73 hospital out-patient departments randomly selected from among all the hospital settings that deliver HIV care in metropolitan France. All out-patients aged ≥ 18 years with a diagnosis of HIV infection of at least 6 months' duration and who were either French citizens or immigrants who had been living in France for at least 6 months were eligible for inclusion. In each participating department, a sample of eligible patients randomly selected according to the order of their appointment were invited to participate by their physician. The 3022 participants included in the ANRS-Vespa2 study signed an informed consent form and answered a standardized questionnaire, administered face to face by a trained interviewer, containing detailed questions about their socioeconomic status, living conditions, health behaviours and health care use (including cancer screening). Clinical and laboratory data were collected from their medical records. Individual weights were computed to account for unequal probabilities of sampling and for characteristics associated with nonparticipation. The study was approved by the French National Commission for Data Protection and Liberties (CNIL).
The data for the general population were obtained from the Barom etre Cancer 2010 survey on knowledge, attitudes, practices and beliefs regarding cancer, which was conducted in 2010 by the French Institute for Health Promotion and Health Education (INPES) and the National Cancer Institute (INCa). The data were obtained by telephone interviews among a national representative sample of 3727 noninstitutionalized individuals aged 15-85 years [42] .
Data collection
Cancer screening uptake was assessed through the same standardized questions in both surveys. The participants were asked whether they had ever had a mammogram or a Papanicolaou (Pap) test and when they had last had it. They could respond by giving the number of years since the last test or the calendar year in which they had had it. In all women aged 50-75 years, a mammogram is advised every 2 years [8] . Therefore, we considered that women aged 50-75 years in both surveys were up to date with BCS if they reported having had a mammogram within the 2 years or 2 calendar years preceding the interview. In women in the general population aged 25-65 years, a Pap test every 3 years is advised, while in HIV-women an annual Pap test is recommended (or a Pap test twice a year for women with a CD4 count < 200 cells/lL) [8] . We therefore considered that women aged 25-65 years in both surveys were up to date with CCS according to the general population guidelines if they reported having had a Pap test within the 3 years or 3 calendar years preceding the interview and that HIVinfected women in the ANRS-Vespa2 survey were up to date with CCS according to the HIV-specific guidelines if they reported having had a Pap test in the preceding year/calendar year.
Other indicators of interest known to be associated with the level of cancer screening were available in both surveys. Sociodemographic characteristics were collected, including age and household composition (whether living in a cohabiting couple or living with children < 14 years of age). Additionally, nationality and country of birth were collected in the HIV-infected sample. HIV-infected women were classified into three mutually exclusive socioepidemiological groups: former or active injecting drug users (IDUs), non-IDU migrants originating from sub-Saharan Africa (SSA migrants) and non-IDU nonAfrican women. The socioeconomic characteristics were educational level [low (no diploma or primary school), intermediate (high school) or high (above high school)], employment status (employed, unemployed, retired, or other inactive/people with a disability) and income [defined as the monthly income per consumption unit and dichotomized according to the median in the general population as low (< €1466) or high (≥ €1466)]. The data on health care coverage included the type of coverage [standard health insurance, health insurance for the disadvantaged ('couverture maladie universelle' (CMU)) or health insurance for undocumented foreigners ('aide m edicale de l'Etat' (AME))] and access to supplementary health insurance. Health care use was measured by the frequency of visits to a general practitioner (GP) (at least one visit in the past year) and to a gynaecologist (at least one visit in the past 2 years in the general population and annual visits in the HIV-infected population). The indicators concerning health behaviours included body mass index (BMI), tobacco smoking (current smokers vs. nonsmokers, including past smokers) and alcohol consumption (none, moderate or risky, assessed through the Alcohol Use Disorder Identification Test (AUDIT-C) AUDIT-C (Alcohol Use Disorder Identification Test) scale [43] ). In the HIV-infected sample, the available information on HIV characteristics included the time since HIV diagnosis (< 8, 8-16 
Statistical analyses
Analyses of BCS were conducted among women aged 50-75 years who did not report a personal history of breast malignancy. Analyses of CCS were performed among women aged 25-65 years, excluding those who had undergone a hysterectomy or who reported a personal history of cervical cancer. In all the analyses, women were included if they had complete data. Missing values were rare (< 5%) for all the covariates, except income in the general population sample (13.8% and 7.2% among the women eligible for BCS and CCS, respectively) and BMI in the HIV-infected population sample (7.1% and 6.6% among the women eligible for BCS and CCS, respectively).
We used direct standardization to estimate age-standardized rates of BCS and CCS among the HIV-infected women, considering women in the general population as the reference. In addition, we computed age-adjusted prevalence rate ratios (aPRRs) to compare the proportions of women who were up to date with BCS and CCS between the HIV-infected and the general population, using Poisson regression models with robust variance.
The factors associated with being up to date with BCS and CCS were investigated in the HIV-infected women using Poisson regression models with robust variance. The covariates included in the models were sociodemographic and economic characteristics, indicators of health care coverage, health care use, health behaviours and HIV characteristics. Multivariate models were constructed by stepwise regressions using backward elimination until all the covariates had a P-value < 0.10. In a sensitivity analysis, models including all the HIV-infected women were run to check that the restriction to the age range of 25-65 years did not change the results.
Then, in order to compare the correlates of BCS and CCS between the HIV-infected women and the general population, multivariate models including both samples were run. The models included the interaction terms between each covariate and the study population. They did not include the country of birth/nationality or HIV characteristics, as they were not available from or relevant to the Barom etre Cancer 2010 survey. To check that this did not affect our results, we performed sensitivity analyses stratifying by nationality in the HIV-infected women.
All the analyses were performed using STATA/SE12 â (Stata Corporation, College Station, TX) and accounted for the sampling design and the data weighting so that the estimates would be representative of the entire HIV-infected population followed at hospitals in France in 2011.
Results
Breast cancer screening
The BCS study population consisted of 225 HIV-infected women and 661 women from the general population aged 50-75 years (Table 1) . Among the former, the median time since HIV diagnosis was 16 years, and 66.2% of them had a CD4 count > 500 cells/lL. Female IDUs accounted for 14.7% of the HIV-infected women, immigrants originating from sub-Saharan Africa accounted for 25.3% and non-IDU non-African women accounted for 60.0%. The median age was 56 years in the HIV-infected women, and 59 years in women from the general population.
Of the HIV-infected women, 84.6% had had a mammogram within the 2 years preceding the interview. The age-standardized rate of up-to-date BCS in the HIVinfected women was 80.7% [95% confidence interval (CI) 70.3-88.1] compared with 89.1% of women in the general population. When age was controlled for, the rate of BCS between the HIV-infected women and the general population was not different (aPRR 0.94; 95% CI 0.87-1.02; P = 0.146).
In univariate analyses (Table 2) , the factors significantly associated with lower BCS uptake in the HIV-infected women were a low/intermediate (vs. high) educational level (PRR 0.83; 95% CI 0.75-0.92), irregular (vs. regular) gynaecological follow-up (PRR 0.74; 95% CI 0.60-0.90) and a CD4 count < 500 (vs. > 500) cells/lL (PRR 0.79; 95% CI 0.66-0.94). In addition, being unemployed/inactive/having a disability (vs. employed) (PRR 0.88; 95% CI 0.77-1.01) and having a low (vs. high) income (PRR 0.88; 95% CI 0.77-1.00) tended to be associated with lower BCS uptake. In the final multivariate model (Table 2) , those with a low/intermediate educational level (aPRR 0.88; 95% CI 0.80-0.97), irregular gynaecological follow-up (aPRR 0.77; 95% CI 0.64-0.92) or a CD4 count < 500 cells/lL (aPRR 0.83; 95% CI 0.71-0.97) were less likely to be up to date with BCS. The correlates of BCS in the HIV-infected population were mostly consistent with those in the general population ( Fig. 1) , with the exception of a low/intermediate educational level, which was associated with higher BCS uptake in the general population but with lower BCS uptake in the HIV-infected women (P-value for interaction: 0.002).
Cervical cancer screening
The CCS study population consisted of 740 HIV-infected women and 1269 women from the general population aged 25-65 years (Table 1) . Among the former, the median time since HIV diagnosis was 10 years. The CD4 count was < 200 cells/lL in 4.6% of them and > 500 cells/lL in 59.2%. Female IDUs accounted for 13.4% of the HIV-infected women, immigrants originating from sub-Saharan Africa accounted for 47.3% and non-IDU non-African women accounted for 39.4%. The median age was 44 years in both the HIV-infected women and the general population, and those aged 35-55 years accounted for 69.6% of the HIV-infected women and 54.8% of women from the general population.
Of the HIV-infected women, 93.3% had had a Pap test since their HIV diagnosis, 88.9% reported having had one within the 3 years preceding the interview, and 76.5% reported having had one in the preceding year. The agestandardized rate of CCS within the preceding 3 years was 88.1% (95% CI 84.5-91.0) in the HIV-infected population compared with 83.1% in the general population. When age was accounted for, the level of CCS was higher in the HIV-infected women than in the general population (aPRR 1.05; 95% CI 1.01-1.10; P = 0.021).
In univariate analyses (Table 3) , the factors significantly associated with lower rates of CCS within the preceding 3 years in the HIV-infected women were a low (vs. high) educational level (PRR 0.87; 95% CI 0.79-0.96), low (vs. high) income (PRR 0.94; 95% CI 0.89-0.99), not having (vs. having) supplementary health insurance (PRR 0.89, 95% CI 0.82-0.96) and irregular (vs. regular) gynaecological follow-up (PRR 0.69; 95% CI 0.61-0.79), while a CD4 count of 350-500 (vs. > 500) cells/lL was associated with higher CCS uptake (PRR 1.06; 95% CI 1.01-1.11). A CD4 count < 200 cells/lL tended to be a predictor of low CCS uptake. In the final multivariate model (Table 3) , the factors associated with CCS uptake within the preceding 3 years in the HIV-infected women were a low educational level (aPRR 0.91; 95% CI 0.83-0.99), not having supplementary health insurance (aPRR 0.92; 95% CI 0.86-0.98), irregular gynaecological follow-up (aPRR 0.72; 95% CI 0.64-0.81), and a CD4 count < 200 cell/lL (aPRR 0.78; 95% CI 0.63-0.98). The results regarding the correlates of CCS uptake in the preceding year in the HIV-infected women were consistent with those reported for CCS uptake within the preceding 3 years (Table 4) . Moreover, the results concerning CCS remained stable in the sensitivity analysis performed on all the HIV-infected women (with no age restriction).
The associations with CCS uptake within the preceding 3 years were consistent between the HIV-infected women and the general population (Fig. 2) in terms of educational level, income and supplementary insurance. However, the associations between low CCS uptake and younger age (P-value for interaction: 0.03), being unemployed (P-value for interaction: 0.03) and irregular gynaecological follow-up (P-value for interaction: < 0.001) were significantly less pronounced in the HIVinfected women than in the general population.
Discussion
Our findings show that 84.6% of the HIV-infected women had undergone BCS within the preceding 2 years and that 88.9% had undergone CCS within the preceding 3 years. However, almost 1 in 4 of the HIV-infected women had not had CCS in the preceding year. The level of BCS was similar while that of CCS was 5% higher in the HIVinfected women compared with the general population. Moreover, the HIV-infected women had a specific profile regarding barriers to screening uptake. Final multivariate model constructed by stepwise regressions using backward elimination until all the covariates in the univariate analysis had a P-value < 0.10. PRR, prevalence rate ratio; CI, confidence interval; aPRR, adjusted prevalence rate ratio; IDU, injecting drug user; SSA, sub-Saharan Africa; CMU, 'couverture maladie universelle', health insurance for the disadvantaged; AME, 'aide m edicale de l'Etat', health insurance for undocumented foreigners; GP, general practitioner; BMI, body mass index.
In this study, we were able to provide rates of BCS and CCS among HIV-infected women based on recent data and on definitions of screening uptake consistent with the national guidelines. Our findings show a higher level of BCS among HIV-infected women than those previously reported in the literature [21] [22] [23] [24] [25] [26] . This difference could be explained by the level of screening having being assessed through very different methods (mostly medical records [23] [24] [25] [26] ) and/or indicators (a mammogram in the preceding year [21, 24, 25] , in the past 5 years [21] or during the follow-up period [22, 23] ) in those previous studies. Moreover, although we found a high level of CCS within the preceding 3 years, CCS uptake among the HIV-infected women in the preceding year was suboptimal. The proportion of HIV-infected women who reported having undergone CCS in the preceding year was consistent with previous studies based on self-reported data and on comparable indicators [20, 27, [30] [31] [32] [33] 44] .
Additionally, we were able to compare the levels of screening between the HIV-infected women and the general population using indicators collected through the same standardized questions in both data sets and controlling for age, which enabled us to account for demographic differences between the two populations. We found a similar level of BCS in the HIV-infected women and in the general population, a finding inconsistently reported in previous studies [21, 22, 24] . In contrast, our results indicate that HIV-infected women have a higher rate of CCS than women in the general population. Previous studies generally suggested a lower [24, 36, 37] or similar [29, 30] CCS uptake in HIV-infected women compared with women in the general population. However, only one [37] accounted for differences in the age distribution Factors associated with being up to date with breast cancer screening in the HIV-infected population (black triangles) and in the general population (grey dots) in Poisson multivariate regression models. The final multivariate model was constructed by stepwise regression using backward elimination until all the covariates in the univariate analysis had a P-value < 0.10. The model included both the HIV-infected and the general population samples and an interaction term between each covariate and the study population. **P-value of the interaction term between each category of the covariates and the study population in the final multivariate model, which included both the HIV-infected sample and general population sample. GP, general practitioner; aPRR, adjusted prevalence rate ratio; BMI, body mass index. The final multivariate model was constructed by stepwise regression using backward elimination until all the covariates in the univariate analysis had a P-value < 0.10. PRR, prevalence rate ratio; CI, confidence interval; aPRR, adjusted prevalence rate ratio; IDU, injecting drug user; SSA, sub-Saharan Africa; CMU, 'couverture maladie universelle', health insurance for the disadvantaged; AME, 'aide m edicale de l'Etat', health insurance for undocumented foreigners; GP, general practitioner; BMI, body mass index. The final multivariate model was constructed by stepwise regressions using backward elimination until all the covariates in the univariate analysis had a P-value < 0.10. PRR, prevalence rate ratio; CI, confidence interval; aPRR, adjusted prevalence rate ratio; IDU, injecting drug user; SSA, sub-Saharan Africa; CMU, 'couverture maladie universelle', health insurance for the disadvantaged; AME, 'aide m edicale de l'Etat', health insurance for undocumented foreigners; GP, general practitioner; BMI, body mass index.
between the two populations. Thus, our results do not support the hypothesis of lower screening rates among HIV-infected women, even though such a result has been reported among women living with other chronic diseases [45] . Our results suggest that the HIV-specific recommendation of an annual Pap test enhances CCS uptake among HIV-infected women. Our findings suggest that there are potential barriers to screening uptake in PLWHIV. Consistent with previous studies [31, 38, 39] , we found that a poor educational level was a barrier to both BCS and CCS among the HIV-infected women. This may reflect differences in health behaviours, access to care, awareness of the importance of preventive care and/or medical practices according to patients' educational level. Additionally, irregular gynaecological follow-up was associated with lower BCS and CCS uptake among the HIV-infected women, which indicates the major influence of gynaecologists with regard to gynaecological screening. The fact that not having supplementary health insurance is a predictor of low CCS uptake suggests that there are financial barriers to screening access among HIVinfected women, despite the fact that HIV care-related expenses are completely covered by health insurance. Not having supplementary insurance was not a barrier to BCS, which suggests that these financial barriers may have been reduced, thanks to the dedicated national free BCS programme. Consistent with previous research [20, 23, 28, 30, 34] , we found that a low CD4 count was a barrier to both BCS and CCS, which suggests that HIVrelated concerns might preclude attention to other health problems. This result would mean that CCS should be reinforced among women with a low CD4 count, who are at higher risk for cervical cancer.
Finally, we were able to formally compare the determinants of cancer screening uptake between PLWHIV and Factors associated with being up to date with cervical cancer screening according to the general population guidelines in the HIVinfected population (black triangles) and in the general population (grey dots) in Poisson multivariate regression models. The final multivariate model was constructed by stepwise regression using backward elimination until all the covariates in the univariate analysis had a P-value < 0.10. The model included both the HIV-infected and the general population samples and an interaction term between each covariate and the study population. **P-value of the interaction term between each category of the covariates and the study population in the final multivariate model, which included both the HIV-infected sample and the general population sample. aPRR, adjusted prevalence rate ratio.
the general population. We found that HIV-infected women presented certain particularities. With regard to BCS uptake, we identified specific disparities according to educational level among HIV-infected women that were not observed in the general population. However, the disparities in CCS uptake according to age, employment and gynaecological follow-up were less pronounced in the HIV-infected women than in the general population. This suggests that the HIV-specific screening guidelines may reduce disparities in access to CCS, unlike the situation we observed for BCS, which is not the subject of a specific recommendation among HIV-infected women. Therefore, better integration of BCS as part of HIV care might help reduce disparities.
The main strength of our study is its nationally representative design, which enabled us to provide detailed data on cancer screening practices that are generalizable to the entire population of PLWHIV followed at hospitals in France, where the health system provides free access to care. To our knowledge, this is the first study that provides such data in France and that formally compares screening levels and predictors between the HIV-infected and general populations. However, our study has some potential limitations. First, we may have overestimated the level of screening uptake because we used self-reported data [46] [47] [48] and allowed a certain amount of leeway in the estimation of the length of time since the last test by using the calendar year instead of the exact date (even though this is a common practice [23, 34, 37, 38] ). However, as the data collection and the outcome definition were identical in both surveys, it seems unlikely that this potential overestimation had an impact on the results of the comparisons between PLWHIV and the general population. In addition, we cannot exclude a possible bias in the analyses comparing HIV-infected women and women of the general population, as a result of a difference in data collection modalities (face to face vs. telephone interview, respectively). However, a previous study suggested that telephone and face-to-face interviews provided similar information for various indicators of health practices and health behaviours, including uptake of cancer screening [49] . Also, in our study, we could not account for geographical origin/nationality. However, the findings concerning the association between nationality and BCS or CCS in the literature are inconsistent [39] ; also, in univariate analyses we did not find a significant difference in screening rates according to geographical origin (SSA migrants vs. non-IDU non-African women), and the sensitivity analyses that we performed by stratifying the HIV-infected population according to nationality led to the same conclusions as our main results. Moreover, our findings do not apply to HIV-infected individuals who are not hospital out-patients. However, they represent a very small proportion of all PLWHIV [50] , especially as at least one annual hospital visit is recommended for all PLWHIV in France [8] .
In conclusion, our findings provide new evidence for better addressing barriers to BCS and CCS in HIV-infected women and for improving cancer screening and risk management. Overall, the level of BCS was relatively high, but more attention is needed to reduce the remaining disparities. Although HIV-specific guidelines seem to have a positive impact on CCS uptake, the level of screening is suboptimal, considering the elevated risk of cervical cancer in this population. Both BCS and CCS should better target those who are less educated or with a low CD4 count. Preventive care should be strengthened, and PLWHIV should be advised to seek comprehensive care at the primary care level to take advantage of the entire range of health/medical follow-up activities, including cancer screening.
